Resonance Health (RHT.AX) Stock Price

Resonance Health Price

ASX·CLOSED
0.05AUD+0.0030 (+6.59 %)
Market closed

Revenue has compounded at 16.4% per year over the past 19 years to 11.16 M AUD. Earnings per share have declined at 9.8% per year over the last 15 years. Resonance Health's net margin stands at -15.5%, down from 15.4% several years earlier. The stock trades about 42% above its 52-week low.

Resonance Health stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Resonance Health over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Resonance Health stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Resonance Health's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Resonance Health Stock Price History
DateResonance Health Price
7/14/20260.05 AUD
7/13/20260.04 AUD
7/10/20260.05 AUD
7/9/20260.05 AUD
7/8/20260.05 AUD
7/7/20260.05 AUD
7/6/20260.05 AUD
7/3/20260.05 AUD
7/2/20260.05 AUD
7/1/20260.05 AUD
6/30/20260.04 AUD
6/29/20260.04 AUD
6/26/20260.05 AUD
6/25/20260.05 AUD
6/24/20260.05 AUD
6/23/20260.04 AUD
6/22/20260.05 AUD
6/19/20260.05 AUD
6/18/20260.04 AUD
6/17/20260.04 AUD
6/16/20260.04 AUD
6/15/20260.04 AUD
6/12/20260.04 AUD
6/11/20260.04 AUD
6/10/20260.04 AUD
6/9/20260.04 AUD
6/5/20260.04 AUD
6/4/20260.04 AUD
6/3/20260.04 AUD
6/2/20260.04 AUD
6/1/20260.04 AUD
5/29/20260.04 AUD
5/28/20260.04 AUD
5/27/20260.04 AUD
5/26/20260.04 AUD
5/25/20260.04 AUD
5/22/20260.04 AUD
5/21/20260.04 AUD
5/20/20260.04 AUD
5/19/20260.04 AUD
5/18/20260.04 AUD
5/15/20260.04 AUD
5/14/20260.04 AUD
5/13/20260.04 AUD
5/12/20260.04 AUD
5/11/20260.04 AUD
5/8/20260.05 AUD
5/7/20260.05 AUD
5/6/20260.05 AUD
5/5/20260.05 AUD
5/4/20260.05 AUD
5/1/20260.05 AUD
4/30/20260.05 AUD
4/29/20260.05 AUD
4/28/20260.04 AUD
4/27/20260.04 AUD
4/24/20260.04 AUD
4/23/20260.04 AUD
4/22/20260.04 AUD
4/21/20260.04 AUD
4/20/20260.04 AUD
4/17/20260.04 AUD
4/16/20260.04 AUD
4/15/20260.04 AUD
4/14/20260.04 AUD
4/13/20260.04 AUD
4/10/20260.04 AUD
4/9/20260.04 AUD
4/8/20260.04 AUD
4/7/20260.04 AUD
4/2/20260.04 AUD
4/1/20260.04 AUD
3/27/20260.04 AUD
3/26/20260.04 AUD
3/25/20260.04 AUD
3/24/20260.04 AUD
3/23/20260.04 AUD
3/20/20260.04 AUD
3/17/20260.04 AUD
3/16/20260.04 AUD
3/13/20260.04 AUD
3/12/20260.04 AUD
3/11/20260.04 AUD
3/10/20260.04 AUD
3/9/20260.04 AUD
3/6/20260.04 AUD
3/4/20260.04 AUD
3/2/20260.04 AUD
2/25/20260.05 AUD
2/23/20260.04 AUD
2/18/20260.05 AUD
2/17/20260.05 AUD
2/16/20260.04 AUD
2/12/20260.04 AUD
2/10/20260.05 AUD
2/6/20260.04 AUD
2/4/20260.05 AUD
2/3/20260.05 AUD
2/2/20260.04 AUD
1/30/20260.04 AUD
1/29/20260.04 AUD
1/27/20260.04 AUD
1/23/20260.04 AUD
1/22/20260.04 AUD
1/21/20260.04 AUD
1/19/20260.04 AUD
1/14/20260.05 AUD
1/13/20260.05 AUD
1/12/20260.05 AUD
1/9/20260.05 AUD
1/8/20260.05 AUD
1/6/20260.05 AUD
1/5/20260.05 AUD
1/2/20260.05 AUD
12/31/20250.05 AUD
12/29/20250.05 AUD
12/23/20250.04 AUD
12/22/20250.05 AUD
12/19/20250.04 AUD
12/18/20250.04 AUD
12/17/20250.05 AUD
12/16/20250.05 AUD
12/15/20250.05 AUD
12/12/20250.05 AUD
12/11/20250.05 AUD
12/10/20250.05 AUD
12/8/20250.05 AUD
12/5/20250.05 AUD
12/4/20250.05 AUD
12/3/20250.05 AUD
12/1/20250.05 AUD
11/28/20250.05 AUD
11/27/20250.05 AUD
11/26/20250.05 AUD
11/25/20250.05 AUD
11/24/20250.05 AUD
11/21/20250.04 AUD
11/20/20250.05 AUD
11/19/20250.05 AUD
11/18/20250.05 AUD
11/17/20250.05 AUD
11/14/20250.05 AUD
11/12/20250.05 AUD
11/11/20250.05 AUD
11/10/20250.05 AUD
11/7/20250.05 AUD
11/5/20250.05 AUD
11/4/20250.05 AUD
10/31/20250.05 AUD
10/30/20250.05 AUD
10/29/20250.05 AUD
10/24/20250.05 AUD
10/23/20250.05 AUD
10/22/20250.05 AUD
10/21/20250.05 AUD
10/20/20250.05 AUD
10/17/20250.05 AUD
10/16/20250.06 AUD
10/15/20250.05 AUD
10/14/20250.05 AUD
10/13/20250.04 AUD
10/10/20250.04 AUD
10/9/20250.04 AUD
10/8/20250.04 AUD
10/7/20250.04 AUD
10/6/20250.04 AUD
10/3/20250.04 AUD
10/2/20250.04 AUD
10/1/20250.04 AUD
9/30/20250.04 AUD
9/26/20250.04 AUD
9/25/20250.04 AUD
9/24/20250.04 AUD
9/19/20250.03 AUD
9/18/20250.04 AUD
9/17/20250.03 AUD
9/16/20250.04 AUD
9/15/20250.04 AUD
9/12/20250.04 AUD
9/11/20250.03 AUD
9/9/20250.03 AUD
9/8/20250.04 AUD
9/5/20250.03 AUD
9/4/20250.04 AUD
9/3/20250.03 AUD
9/2/20250.03 AUD
9/1/20250.04 AUD
8/29/20250.04 AUD
8/28/20250.04 AUD
8/27/20250.04 AUD
8/26/20250.04 AUD
8/25/20250.04 AUD
8/22/20250.05 AUD
8/21/20250.04 AUD
8/20/20250.04 AUD
8/18/20250.04 AUD
8/15/20250.04 AUD
8/14/20250.04 AUD
8/13/20250.04 AUD
8/12/20250.04 AUD
8/11/20250.04 AUD
8/8/20250.04 AUD
8/7/20250.04 AUD
8/6/20250.04 AUD
8/4/20250.04 AUD
8/1/20250.04 AUD
7/31/20250.04 AUD
7/28/20250.04 AUD
7/24/20250.04 AUD
7/23/20250.04 AUD
7/22/20250.04 AUD
7/21/20250.04 AUD
7/17/20250.04 AUD
Access this data via the Eulerpool API
Get Free API Key

Resonance Health Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
2.91 M AUD
-246,300.00 AUD
224,600.00 AUD
Jan 1, 2019
3.66 M AUD
904,300.00 AUD
1.27 M AUD
Jan 1, 2020
3.71 M AUD
-1.14 M AUD
-715,100.00 AUD
Jan 1, 2021
3.82 M AUD
225,700.00 AUD
585,900.00 AUD
Jan 1, 2022
3.83 M AUD
-1.77 M AUD
-1.14 M AUD
Jan 1, 2023
4.51 M AUD
-1.52 M AUD
-780,400.00 AUD
Jan 1, 2024
8.80 M AUD
-665,300.00 AUD
169,300.00 AUD
Jan 1, 2025
11.16 M AUD
-1.84 M AUD
-1.73 M AUD

Resonance Health Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 17, 2026, 1:02 AM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025
2.001.001.001.002.002.002.002.002.003.003.003.003.004.008.0011.00
–-50.00––100.00––––50.00–––33.33100.0037.50
-50.00-100.00-100.00-100.00-50.00-50.00-50.00-50.00-50.00-33.33-33.33-33.33-33.33-25.00-12.50-9.09
-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00
–––––––––1.00––-1.00––-1.00
––––––––––––––––
364.36364.89365.11365.11363.57398.24401.57402.47402.50405.84432.39452.24461.15461.15468.47455.31
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Resonance Health generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Resonance Health retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Resonance Health's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Resonance Health has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Resonance Health's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Resonance Health stock margins

The Resonance Health margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Resonance Health. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Resonance Health.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
0.00 %
-8.46 %
7.71 %
Jan 1, 2019
0.00 %
24.70 %
34.69 %
Jan 1, 2020
0.00 %
-30.69 %
-19.28 %
Jan 1, 2021
0.00 %
5.91 %
15.35 %
Jan 1, 2022
0.00 %
-46.17 %
-29.80 %
Jan 1, 2023
0.00 %
-33.65 %
-17.30 %
Jan 1, 2024
0.00 %
-7.56 %
1.92 %
Jan 1, 2025
0.00 %
-16.49 %
-15.53 %

Resonance Health Stock Revenue, EBIT, Earnings per Share

The Resonance Health earnings per share therefore indicates how much revenue Resonance Health has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.01 AUD
-0.00 AUD
0.00 AUD
Jan 1, 2019
0.01 AUD
0.00 AUD
0.00 AUD
Jan 1, 2020
0.01 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2021
0.01 AUD
0.00 AUD
0.00 AUD
Jan 1, 2022
0.01 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2023
0.01 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2024
0.02 AUD
-0.00 AUD
0.00 AUD
Jan 1, 2025
0.02 AUD
-0.00 AUD
-0.00 AUD

Resonance Health business model & stock analysis

Resonance Health Ltd is an Australian company that operates in the medical technology industry. The company's business model is to offer groundbreaking solutions for the diagnosis and treatment of liver and iron diseases. As a pioneering company in the development of methods and technologies for quantifying liver and iron concentrations, Resonance Health continually sets new standards in the industry. The company was founded in 2000 by a team of biomedicine professionals from the University of Western Australia. Over the years, the company has gained a lot of experience and constantly evolved to keep up with the progress of medical technology. The goal is to provide patients with better treatment and improved quality of life. One division of the company is the development and manufacturing of diagnostic tools for quantifying liver and iron diseases such as hepatitis, fatty liver, or hemochromatosis. The quantification method used by Resonance Health is called FerriScan. This method is non-invasive and painless, using magnetic resonance imaging (MRI) to measure the concentration of iron in the tissue. This is particularly important as a change in iron content can indicate a progressing liver disease. In addition to the FerriScan diagnostic tool, Resonance Health also offers a software package for analyzing FerriScan results, which is used by physicians and clinicians to assess disease progression. Furthermore, the company also develops solutions in the field of hemochromatosis, a genetic disorder that can lead to increased iron levels in the body. Another division of Resonance Health is the provision of research and development services to further develop and improve FerriScan and other technologies. The company collaborates with other companies, scientific institutions, and universities to advance the current developments in liver and iron diagnostics. Resonance Health has a range of products that contribute to better diagnosis and treatment of liver and iron diseases. These include FerriScan, the FerriSmart software package for precise monitoring of iron and liver health, and Hepatica, a software supporting hospitals and clinics in the diagnosis of liver diseases. The company is an innovative leader in the industry, contributing to improving the quality of life for patients. The products and services of Resonance Health have helped doctors and clinicians to effectively treat and diagnose liver and iron diseases. Additionally, the company has established a strong scientific foundation and works closely with leading institutions to continuously develop innovative solutions. Resonance Health is a company with a rich history that continues to evolve to meet the demands of the medical technology industry. The company aims to continuously improve the diagnosis and treatment of liver and iron diseases and offer better solutions.

Resonance Health SWOT Analysis

Strengths

1. Advanced Technology: Resonance Health Ltd has developed cutting-edge technology in the field of medical imaging, allowing for accurate and non-invasive diagnosis.

2. Strong Intellectual Property: The company possesses a robust portfolio of patents and intellectual property rights, providing a competitive advantage and potential revenue streams.

3. Established Market Presence: Resonance Health Ltd has built a solid reputation and strong relationships with key stakeholders in the healthcare industry, including hospitals, clinics, and research institutions.

Weaknesses

1. Limited Market Reach: Despite its achievements, Resonance Health Ltd still faces challenges in expanding its market reach, particularly in emerging markets where healthcare infrastructure may be underdeveloped.

2. Reliance on Partnerships: The company relies heavily on strategic partnerships for distribution and marketing, which could potentially limit its control over pricing and market positioning.

3. High Research and Development Costs: Developing and improving advanced medical imaging technology requires substantial investment, placing financial strain on Resonance Health Ltd.

Opportunities

1. Growing Demand for Medical Imaging: The increasing global prevalence of chronic diseases and aging populations create a significant opportunity for Resonance Health Ltd to tap into the growing demand for accurate and efficient medical imaging solutions.

2. Expansion into New Markets: By exploring partnerships or establishing subsidiaries in untapped markets, Resonance Health Ltd can diversify its revenue streams and expand its customer base.

3. Technological Advancements: With ongoing advancements in technology, there is potential for Resonance Health Ltd to further enhance its imaging solutions, improving accuracy and efficiency.

Threats

1. Intense Competitive Landscape: The medical imaging industry is highly competitive, with existing players and new entrants constantly striving to develop and market innovative solutions. Resonance Health Ltd must ensure it stays ahead of competitors.

2. Regulatory and Compliance Challenges: Compliance with stringent regulatory requirements, such as obtaining necessary approvals and maintaining quality standards, poses challenges and potential delays for Resonance Health Ltd.

3. Economic Volatility: Fluctuations in global economies and healthcare spending can impact the purchasing power of customers and healthcare providers, potentially affecting the demand for Resonance Health Ltd's products.

Resonance Health Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Resonance Health historical P/E ratio, EBIT multiple, and P/S ratio

Resonance Health annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Resonance Health shares outstanding

The number of shares of Resonance Health was 455.31 M in 2025. This indicates how many shares Resonance Health is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
402.50 M Stocks
Jan 1, 2019
405.84 M Stocks
Jan 1, 2020
432.39 M Stocks
Jan 1, 2021
452.24 M Stocks
Jan 1, 2022
461.15 M Stocks
Jan 1, 2023
461.15 M Stocks
Jan 1, 2024
468.47 M Stocks
Jan 1, 2025
455.31 M Stocks

Resonance Health stock splits

In Resonance Health's history, there have been no stock splits.
Price targets and forecasts for Resonance Health are not yet available.

Resonance Health shareholder structure

% Name
16.54851%
Panton (Simon Timothy)
Panton (Simon Timothy)
2.03161%
Van Dyk (Paul John)
Van Dyk (Paul John)
1.46246%
Thompson (William Murray)
Thompson (William Murray)
1.43041%
Thompson (Jade Louise)
Thompson (Jade Louise)
1.42761%
Garg (Harish)
Garg (Harish)
1.41985%
Blake (Martin Peter)
Blake (Martin Peter)

Resonance Health Executives and Management Board

MW

Mr. Mitchell Wells

(47)

Company Secretary, Non-Executive Director · since 2018

Compensation260,000.00 AUD
NA

Mr. Nick Allan

Chief Operating Officer, Chief Financial Officer & Joint Company Secretary

Compensation225,000.00 AUD
TP

Dr. Timothy St. Pierre

Chief Research Scientist · since 2006

Compensation67,119.00 AUD
MB

Dr. Martin Blake

Independent Non-Executive Chairman of the Board

Compensation59,999.00 AUD
SP

Mr. Simon Panton

Non-Executive Director

Compensation40,000.00 AUD

Frequently asked questions about Resonance Health

The business model of Resonance Health Ltd focuses on providing innovative medical imaging software and services. The company aims to improve patient care and outcomes through its advanced technology solutions. Resonance Health specializes in the development and commercialization of non-invasive diagnostic tools, particularly in the field of liver and cardiac diseases. By leveraging its expertise in quantitative analysis and iron overload assessment, Resonance Health offers reliable and efficient solutions for diagnosing and managing various health conditions. The company operates by licensing its software to medical institutions and partnering with healthcare providers, ensuring widespread accessibility and utilization of its cutting-edge technologies.

All fundamentals and in-depth analysis of Resonance Health

Our stock analysis for Resonance Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Resonance Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Resonance Health Stock
Resonance Health Revenue→
Resonance Health Stock
Resonance Health Net Income→
Resonance Health Stock
Resonance Health P/E→
Resonance Health Stock
Resonance Health P/S→
Resonance Health Stock
Resonance Health EBIT→
Resonance Health Stock
Resonance Health Dividend→
Resonance Health Stock
Resonance Health Directors Dealings→
Resonance Health Stock
Resonance Health Stocks→
Resonance Health Stock
Resonance Health Market capitalization→
Resonance Health Stock
Resonance Health Debt→
Resonance Health Stock
Resonance Health Liabilities→
Resonance Health Stock
Resonance Health Equity→
Resonance Health Stock
Resonance Health AAQS→
Resonance Health Stock
Resonance Health Employees→
Resonance Health Stock
Resonance Health ROE→
Resonance Health Stock
Resonance Health ROA→
Resonance Health Stock
Resonance Health ROCE→
Resonance Health Stock
Resonance Health News→
Resonance Health Stock
Resonance Health Analyst Price Targets→

Health Stocks

Respiratorius AB (publ)ResmedResponse GeneticsResapp HealthRestart Life SciencesRepublic HealthcareRetinalGenix TechnologiesReproCellRetractable TechnologiesReplimune GroupRetrieve Medical HoldingsRepligenAll Stocks A–Z →